BTK and lymphoma: Interestingly, BTK inhibition can indirectly downregulate PD-L1 signaling in DLBCL cells [132], and enhance the anti-tumour therapeutic effects of PD-1 blockade in mouse models of lymphoma [226], which might be proven synergistic with anti-PD-1 immunotherapy (NCT02362035) [227].